NCT01222780: To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer |
|
|
| Completed | 1 | 22 | US | Marqibo, Vincristin Sulfate Liposomal Injection | Acrotech Biopharma LLC, National Cancer Institute (NCI) | Sarcoma, Neuroblastoma, Wilms Tumor, Leukemia, Lymphoma, Brain Tumors | 12/14 | 12/14 | | |
